First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
verfasst von:
Adrienne H. Brouwers, Joyce van Sluis, Johannes H. van Snick, Carolina P. Schröder, Inge O. Baas, Ronald Boellaard, Andor W. J. M. Glaudemans, Ronald J. H. Borra, Adriaan A. Lammertsma, Rudi A. J. O. Dierckx, Charalampos Tsoumpas
This article is part of the Topical Collection on Image of the month
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Long axial field-of-view (LAFOV) PET/CT scanners have been introduced recently [1, 2], which offer numerous advantages [3]. One important advantage of using LAFOV PET/CT for imaging 89Zr-labelled monoclonal antibodies (mAbs), i.e., immunoPET, is the substantial increase in sensitivity compared with standard axial field-of-view (SAFOV) PET/CT systems, which may lead to a remarkable image quality improvement. This first study showcases such improvement for immunoPET with Biograph Vision Quadra™ (VQ) LAFOV PET/CT (Siemens Healthineers, Knoxville, TN, USA).
Two patients suffering from metastatic HER2-positive breast cancer were administered with 37 MBq [89Zr]trastuzumab in order to assist clinical decision-making [4, 5]. Patients were scanned 4 days postinjection with a Biograph™ mCT PET/CT (patient A) or a Biograph Vision™ PET/CT (patient B) (Siemens Healthineers, Knoxville, TN, USA), according to local standard operating procedures with overall scan durations of 45 min and 32 min, for, respectively, mCT and Vision. Following the clinical scans, patients were scanned with VQ. For VQ, we choose to apply a long scan duration of 30 min (patient A) and 32 min (patient B) to improve image quality rather than shortening the overall scan duration, as compared to Vision. For SAFOV systems, the acquisition and reconstruction parameters complied with EARL1, whilst for LAFOV, we also applied clinically (CLIN) recommended settings (Table 1) [6, 7].
Table 1
Acquisition and reconstruction parameters for the different systems
EARL European Association of Nuclear Medicine Research Ltd., OSEM 3D ordered subset expectation maximization with time-of-flight and point spread function, i iterations, s subsets, FWHM full width at half maximum
Anzeige
PET/CT images of patient A are shown in the top two rows (a-h), for patient B in the bottom rows (i-p). The same intensity scale, SUV range 0–10, applies for all images, except the fused images (e, m). Additional reconstructions of the Vision Quadra data were obtained, mimicking 3-min (d, h, l, p) and 10-min (c, g, k, o) acquisitions, illustrating more pragmatic scan durations.
As can be appreciated from these first human immunoPET images on a LAFOV system, the image quality improvement (f) is most spectacular when compared with the mCT (a). For example, in patient A, an additional small bone lesion was visualized with VQ in the pelvic area (f), which was not visible with the SAFOV system (a). Even when compared to the Vision (i), the VQ image (n) shows improved quality without applying any filter after reconstruction. Moreover, this image quality was improved even in the 10 min image compared with the 30–45 min acquisition needed for SAFOV systems.
Thus, this image shows that the large axial FOV system provides substantial improvement in image quality when applying currently preferred overall scan durations on SAFOV systems (45 min for mCT, 32 min for Vision). Additionally, with the new LAFOV system, there is room for further reduction of the overall scan duration with still very acceptable image quality, even for 89Zr-labelled mAb PET/CT studies.
×
Declarations
Ethics approval and consent to participate
The medical Ethics Review Board of the University Medical Center Groningen waived the need for formal ethical review of the validation protocol of the Vision Quadra PET/CT system (waiver number METc2020/554). Both patients were informed about the study aims, procedures (one additional PET/CT scan on the same day with the planned PET/CT), and the need to acquire an additional low-dose CT scan. Informed consent was obtained before the start of the second acquisition on the LAFOV PET/CT system.
Anzeige
Consent for publication
Both patients gave written informed consent to anonymously use their clinical and imaging data for publication.
Conflict of interest
The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.
First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
verfasst von
Adrienne H. Brouwers Joyce van Sluis Johannes H. van Snick Carolina P. Schröder Inge O. Baas Ronald Boellaard Andor W. J. M. Glaudemans Ronald J. H. Borra Adriaan A. Lammertsma Rudi A. J. O. Dierckx Charalampos Tsoumpas
